(BHR) Braemar Hotel & Resorts - Overview
Stock: Luxury Hotels, High-RevPAR Resorts, Urban Properties, Resort Destinations
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 7.62% |
| Yield on Cost 5y | 5.04% |
| Yield CAGR 5y | -12.68% |
| Payout Consistency | 79.4% |
| Payout Ratio | 37.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 55.9% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.50 |
| Alpha | 1.02 |
| Character TTM | |
|---|---|
| Beta | 1.092 |
| Beta Downside | 1.179 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.26% |
| CAGR/Max DD | -0.15 |
Description: BHR Braemar Hotel & Resorts January 03, 2026
Braemar Hotel & Resorts Inc. (NYSE:BHR) is a Maryland-incorporated REIT, formed in April 2013, that targets luxury hotels and resorts with RevPAR at least twice the U.S. national average (≈ $199 for 2024, per STR). The company holds its assets through Braemar OP, an operating partnership, and relies entirely on external service providers-Ashford Hospitality Advisors (a subsidiary of Ashford Inc.) for asset management and third-party hotel operators for day-to-day management. As of September 30 2025, BHR owned interests in 14 properties across 6 states, D.C., Puerto Rico, and St. Thomas, totaling 3,438 rooms (3,298 net of JV interests), with 13 properties owned directly and one via a majority-owned entity.
Key industry metrics that contextualize BHR’s positioning: (1) U.S. luxury-segment RevPAR has been rising ~5% YoY in 2024-25, driven by strong inbound tourism and higher discretionary spending; (2) Occupancy rates for upscale urban hotels are hovering around 78%-above the 71% average for all hotel categories, supporting BHR’s high-RevPAR focus; (3) REIT cap rates for hotel assets have compressed to 5.8%–6.2% in major markets, reflecting investor appetite for income-generating properties with resilient demand generators (e.g., business travel, conventions, and leisure tourism). These drivers suggest that BHR’s portfolio may benefit from both top-line growth and favorable valuation trends, though the company’s reliance on third-party managers introduces execution risk that should be monitored.
If you want a deeper quantitative assessment of BHR’s valuation and risk profile, a look-through of the analysis on ValueRay could be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -7.38m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.11 > 1.0 |
| NWC/Revenue: 12.21% < 20% (prev 17.00%; Δ -4.79% < -1%) |
| CFO/TA 0.02 > 3% & CFO 39.1m > Net Income -7.38m |
| Net Debt (1.07b) to EBITDA (183.3m): 5.83 < 3 |
| Current Ratio: 1.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.2m) vs 12m ago 2.55% < -2% |
| Gross Margin: 24.26% > 18% (prev 0.20%; Δ 2406 % > 0.5%) |
| Asset Turnover: 34.00% > 50% (prev 33.64%; Δ 0.36% > 0%) |
| Interest Coverage Ratio: 0.90 > 6 (EBITDA TTM 183.3m / Interest Expense TTM 99.1m) |
Altman Z'' -0.57
| A: 0.04 (Total Current Assets 255.7m - Total Current Liabilities 168.8m) / Total Assets 2.01b |
| B: -0.26 (Retained Earnings -515.8m / Total Assets 2.01b) |
| C: 0.04 (EBIT TTM 89.4m / Avg Total Assets 2.09b) |
| D: -0.29 (Book Value of Equity -515.2m / Total Liabilities 1.78b) |
| Altman-Z'' Score: -0.57 = B |
Beneish M -3.10
| DSRI: 1.14 (Receivables 64.7m/58.2m, Revenue 711.8m/732.6m) |
| GMI: 0.84 (GM 24.26% / 20.33%) |
| AQI: 1.00 (AQ_t 0.86 / AQ_t-1 0.85) |
| SGI: 0.97 (Revenue 711.8m / 732.6m) |
| TATA: -0.02 (NI -7.38m - CFO 39.1m) / TA 2.01b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of BHR shares?
Over the past week, the price has changed by +9.74%, over one month by +0.69%, over three months by +14.22% and over the past year by +18.61%.
Is BHR a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4 | 36.5% |
| Analysts Target Price | 4 | 36.5% |
| ValueRay Target Price | 3.2 | 10.2% |
BHR Fundamental Data Overview February 05, 2026
P/S = 0.3247
P/B = 0.8855
Revenue TTM = 711.8m USD
EBIT TTM = 89.4m USD
EBITDA TTM = 183.3m USD
Long Term Debt = 1.16b USD (from longTermDebt, last quarter)
Short Term Debt = 5.36m USD (from shortTermDebt, last quarter)
Debt = 1.18b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.07b USD (from netDebt column, last quarter)
Enterprise Value = 1.30b USD (230.7m + Debt 1.18b - CCE 116.3m)
Interest Coverage Ratio = 0.90 (Ebit TTM 89.4m / Interest Expense TTM 99.1m)
EV/FCF = 23.88x (Enterprise Value 1.30b / FCF TTM 54.4m)
FCF Yield = 4.19% (FCF TTM 54.4m / Enterprise Value 1.30b)
FCF Margin = 7.64% (FCF TTM 54.4m / Revenue TTM 711.8m)
Net Margin = -1.04% (Net Income TTM -7.38m / Revenue TTM 711.8m)
Gross Margin = 24.26% ((Revenue TTM 711.8m - Cost of Revenue TTM 539.1m) / Revenue TTM)
Gross Margin QoQ = 11.01% (prev 25.77%)
Tobins Q-Ratio = 0.65 (Enterprise Value 1.30b / Total Assets 2.01b)
Interest Expense / Debt = 1.90% (Interest Expense 22.5m / Debt 1.18b)
Taxrate = 4.09% (842.0k / 20.6m)
NOPAT = 85.8m (EBIT 89.4m * (1 - 4.09%))
Current Ratio = 1.52 (Total Current Assets 255.7m / Total Current Liabilities 168.8m)
Debt / Equity = 5.59 (Debt 1.18b / totalStockholderEquity, last quarter 211.9m)
Debt / EBITDA = 5.83 (Net Debt 1.07b / EBITDA 183.3m)
Debt / FCF = 19.64 (Net Debt 1.07b / FCF TTM 54.4m)
Total Stockholder Equity = 556.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.35% (Net Income -7.38m / Total Assets 2.01b)
RoE = -1.33% (Net Income TTM -7.38m / Total Stockholder Equity 556.7m)
RoCE = 5.21% (EBIT 89.4m / Capital Employed (Equity 556.7m + L.T.Debt 1.16b))
RoIC = 6.02% (NOPAT 85.8m / Invested Capital 1.43b)
WACC = 3.14% (E(230.7m)/V(1.42b) * Re(9.94%) + D(1.18b)/V(1.42b) * Rd(1.90%) * (1-Tc(0.04)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.80%
[DCF Debug] Terminal Value 83.88% ; FCFF base≈46.5m ; Y1≈37.5m ; Y5≈25.9m
Fair Price DCF = N/A (negative equity: EV 793.8m - Net Debt 1.07b = -274.6m; debt exceeds intrinsic value)
EPS Correlation: -19.34 | EPS CAGR: -6.57% | SUE: 1.99 | # QB: 2
Revenue Correlation: 22.09 | Revenue CAGR: 2.59% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.16 | Chg30d=-0.140 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-1.80 | Chg30d=-0.330 | Revisions Net=-1 | Growth EPS=-100.0% | Growth Revenue=-2.6%